2020
Glycemic Variability and CNS Inflammation: Reviewing the Connection
Watt C, Sanchez-Rangel E, Hwang JJ. Glycemic Variability and CNS Inflammation: Reviewing the Connection. Nutrients 2020, 12: 3906. PMID: 33371247, PMCID: PMC7766608, DOI: 10.3390/nu12123906.Peer-Reviewed Original ResearchConceptsBlood-brain barrierGlycemic variabilityOxidative stressCentral nervous system outcomesImpact of hyperglycemiaType 2 diabetesCNS inflammationVascular complicationsVascular inflammationCognitive dysfunctionTherapeutic implicationsCognitive deficitsType 1Brain functionNeuroinflammationInflammationDysfunctionGlucoseLow levelsSystem outcomesHigh levelsComplicationsHyperglycemiaDiabetesLatest data
2015
Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV
Valcour VG, Spudich SS, Sailasuta N, Phanuphak N, Lerdlum S, Fletcher JL, Kroon ED, Jagodzinski LL, Allen IE, Adams CL, Prueksakaew P, Slike BM, Hellmuth JM, Kim JH, Ananworanich J. Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV. PLOS ONE 2015, 10: e0142600. PMID: 26555069, PMCID: PMC4640512, DOI: 10.1371/journal.pone.0142600.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyStandard combination antiretroviral therapyLog10 HIV RNAAcute HIVCSF cytokinesHIV RNACentral nervous system outcomesIntegrase inhibitorsGamma-induced protein 10Duration of HIVFiebig stages IAcute HIV infectionHIV RNA levelsCNS outcomesAntiretroviral therapyInflammatory markersWeek 24Antiretroviral treatmentHIV infectionPlasma neopterinRandomized armProspective evaluationMean ageHealthy controlsCCR5 antagonists
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply